Assuring Patient Access in a COVID World

What requirements do Biotech companies need to consider during clinical development to ensure that patients will gain access to their innovative therapies? How must Biotech companies adapt in order to be successful in an increasingly cost-conscious world?


MEL WALKER | Managing Director | BioPharma Futures


DOUG DANISON | Head of Europe | Bluebird Bio
CAROLE LONGSON | Independent Senior Adviser, Life Science Policy, HTA and Market Access | Vice Chair | Medicines Discovery Catapult
TIM HAINES | Chairman and Managing Partner | Abingworth LLP
WILLS HUGHES-WILSON | Chief Patient Access & Commercial Planning | Mereo Biopharma